Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies

Authors

  • Christoph Krisp,

    1. Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia
    2. Faculty of Chemistry and Biochemistry, Department of Analytical Chemistry, Ruhr-University Bochum, Bochum, Germany
    Search for more papers by this author
  • Sarah A. Randall,

    1. Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia
    Search for more papers by this author
  • Matthew J. McKay,

    1. Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia
    2. Australian Proteome Analysis Facility (APAF), Macquarie University, Sydney, Australia
    Search for more papers by this author
  • Mark P. Molloy

    Corresponding author
    1. Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia
    2. Australian Proteome Analysis Facility (APAF), Macquarie University, Sydney, Australia
    • APAF, Macquarie University, Sydney 2109, Australia Fax: +612-9850-6200
    Search for more papers by this author

Abstract

The widespread clinical adoption of protein biomarkers with diagnostic, prognostic and/or predictive value remains a formidable challenge for the biomedical community. From discovery to validation, the path to biomarkers of clinical relevance abounds with many protein candidates, yet so few concrete examples have been substantiated. In this review, we focus on the recent adoption of selected reaction monitoring (SRM) of plasma proteins in the path to clinical use for a broad range of diseases including cancer, cardiovascular disease, genetic disorders and various metabolic disorders. Recent progress reveals a promising outlook for clinical applications using SRM, which now provides the routine analysis of clinically relevant protein markers at low nanogram per millilitre in plasma.

Ancillary